Verastem, Inc. (VSTM) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-04
Business type: Asset play
How it makes money
It earns revenue from selling AVMAPKI FAKZYNJA CO-PACK to healthcare providers, with financial success contingent on market adoption and patient access.
The company commercializes a combination therapy for a specific subset of recurrent cancer patients. Earnings depend on physician prescription rates and the willingness of third-party payors to provide reimbursement for the treatment.
Since receiving accelerated approval, revenue is generated through sales volume in the U.S. market, currently serving as the primary source of product-related income.
What growth costs
It must heavily reinvest in clinical trials, such as RAMP 301, and ongoing research to secure regulatory approvals and expand potential therapy indications.
To maintain and grow, the company allocates substantial capital to late-stage clinical trials required for confirmatory FDA approval. These expenditures are necessary to support the expansion of patient populations and geographic reach.
Additional costs include internal R&D for its pipeline and the maintenance of a commercial sales force to drive product adoption.
What could damage it
Failure to convert the current accelerated approval into a full, expanded indication would permanently impair the drug’s viability and market reach.
Because the product currently holds only accelerated approval, it requires confirmatory trial data to prove efficacy. If trials like RAMP 301 fail to validate the therapy, the regulatory foundation for the drug would collapse, destroying the company's sole commercial product revenue stream.
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.